Abstract
Ultrasound-guided percutaneous ethanol ablation procedures for locoregional recurrences in papillary thyroid carcinoma (PTC) can be repeatedly performed over years. Skin metastases (SM) from PTC generally portend a lethal prognosis. Our patient demonstrates the innovative use in low-risk PTC (LRPTC) of treatment modalities designed to prevent neck re-explorations and capable of eliminating both locoregional recurrences and SM. In 2004, a 48-year-old man presented with neck nodal metastases due to PTC. He underwent a near-total thyroidectomy and nodal dissection, confirming an 8-mm PTC involving two ipsilateral node metastases. Postoperatively, he received two doses of RAI for remnant uptake (cumulative dose 338 mCi); post-therapy scanning was unrevealing. In 2007, he underwent right neck dissection for further node metastases. In 2008, a guided biopsy confirmed a level IV node metastasis. He was referred to our institution for ethanol ablation. Two node metastases were ablated and subsequently disappeared. During 2010-16, he developed a further six node metastases which were treated with ethanol ablation; all disappeared on high-resolution sonography. FDG-PET-CT scans in 2009 and 2016 were negative for distant spread. In 2016, a SM in right neck was removed by dermatologic surgery. In 2017-18 two further SM were excised with negative margins, one after Mohs surgery. He has now been disease-free for twenty months. In conclusion, despite three neck surgeries and two RAI therapies, our patient repeatedly developed both locoregional recurrences and SM. All eleven disease foci were eliminated with minimally invasive procedures which should more often be considered as effective treatment options in LRPTC.